The first-of-its-kind gene-editing tool for sickle cell disease was accelerated to market through a regulatory initiative.
The MHRA said it needed to assess data from multiple sources before adding warnings to COVID shots.
The first-of-its-kind gene-editing tool for sickle cell disease was accelerated to market through a regulatory initiative.
The MHRA said it needed to assess data from multiple sources before adding warnings to COVID shots.